Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of our study was to investigate the relationship between myocardial sympathetic degeneration and nigrostriatal impairment in patients affected by Parkinson’s disease (PD) by means of 123I-metaiodobenzylguanidine (123I MIBG) scintigraphy and N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-[123I]iodophenyl)nortropane (123I FP-CIT) scintigraphy.
Patients and methods
The study involved 37 patients with clinical diagnosis of PD (22 males and 15 females, mean age 62 years (±10), evaluated with 123I FP-CIT single photon emission computed tomography (SPECT) followed by 123I MIBG scintigraphy within 20 (±3) days. Early and delayed anterior chest images were acquired and the heart/mediastinum ratio (H/M ratio) was calculated. Furthermore, the population has been divided on the basis of the main clinical pattern to investigate the possible role of a tremor-dominant or an akinetic-dominant phenotype in this comparison.
In PD population, there were no statistical relationships between early and delayed 123I MIBG cardiac and 123I FP-CIT striatal uptake in contralateral caudate (P > 0.05) and in contralateral putamen (P > 0.05) to the side mainly affected; no statistically significant relationships have been found at any level when considering ipsilateral striatum. We did not find statistically significant relationships when considering the single PD phenotypes.
The results of our study suggest that cardiac sympathetic system and nigrostriatal system are differently affected in PD. In particular, the sympathetic neurodegeneration rate is not related to nigrostriatal degeneration rate and vice versa in our series as detectable scintigraphically.
- Brooks DJ, Pavese N. Imaging non-motor aspects of Parkinson’s disease. Prog Brain Res. 2010;184:205–18. CrossRef
- Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;381:121–34. CrossRef
- Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In: Mardsen CD, Faha S, editors. Movement disorders 2. London: Butterwoths; 1987.
- Chaudhri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–45. CrossRef
- Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126–33. CrossRef
- Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson’s disease. Adv Neurol. 2003;91:183–91.
- Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;66:181–4. CrossRef
- Movement Disorder Society. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Movement disorders. 2003;18:738–50. doi:10.1002/mds.10473.
- Spiegel J, Hellwing D, Samnick S, Jost W, Mollers M, Fassbender K, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. J Neural Tansm. 2007;114:331–5. CrossRef
- Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;14:513–21. CrossRef
- Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord. 2003;18:890–7. CrossRef
- Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:30–5. CrossRef
- Chang LT. A method for attenuation correction in radio nuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638–43.
- Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of 123I-FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med. 1997;24:68–71. CrossRef
- Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6. CrossRef
- Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436–46. CrossRef
- Kägi G, Bhatia KP, Telosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5–12. CrossRef
- Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun. 2005;26:421–6. CrossRef
- Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson’s disease correlate with major autonomic symptoms? Parkinsonism Relat Disord. 2006;12:284–8. CrossRef
- Suzuki M, Urashima M, Oka H, Hashimoto M, Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson’s disease. Neuroreport. 2007;18:1867–70. CrossRef
- Spiegel J, Hellwig D, Farmakis G, Jost WH, Samnick S, Fassbender K, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease. Mov Disord. 2007;22:1004–8. CrossRef
- Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst. 1994;49:81–4. CrossRef
- Spiegel J, Möllers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord. 2005;20:552–61. CrossRef
- Spiegel J, Hellwig D, Jost WH, Farmakis G, Samnick S, Fassbender K, et al. Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson’s Disease. Open Neurol J. 2007;1:1–4.
- Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson’s disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med. 2011;28:881–6.
- Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging. 2010;37:3–11. CrossRef
- Chiaravalloti A, Stefani A, Tavolozza M, Pierantozzi M, Di Biagio D, Olivola E, et al. Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson’s disease: molecular imaging with 123I-MIBG. Mol Med Rep. 2012;6:1337–42.
- Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.
- Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci. 2004;220:105–11. CrossRef
- Schillaci O, Chiaravalloti A, Di Pietro B, Stefani A. Thalamic (123)I FP-CIT uptake in a patient with clinical diagnosis of Parkinson’s disease and depression. Hell J Nucl Med. 2012;15:74–5.
- Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease
Annals of Nuclear Medicine
Volume 27, Issue 5 , pp 444-451
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Parkinson’s disease
- DAT SCAN
- Dopamine transporter
- Noradrenergic system
- Industry Sectors
- Author Affiliations
- 1. Department of Biopathology and Diagnostic Imaging, University Hospital Tor Vergata, Viale Oxford 81, 00173, Rome, Italy
- 2. Department of Neurosciences, University Hospital Tor Vergata, Rome, Italy
- 4. Department of Biopathology and Diagnostic Imaging, University Hospital Tor Vergata, Rome, Italy
- 3. IRCCS Neuromed, Pozzilli, Italy